🇺🇸 US Stock Screener ← Switch market ⚡ HerAI

Inspire Medical Systems, Inc. INSP R3KPHARMA

Healthcare · Medical Devices · United States
https://www.inspiresleep.com
Company Profile ↓
$62.14
-28.87% 1Y
Mkt Cap$1.80B
P/E13.72
P/B2.69
52W High$143.99
52W Low$40.05
Book Value$28.56
EPS (TTM)$4.53

Company Overview

Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for patients with moderate to severe OSA. It also develops a novel, closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The company was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 18.0%, reflecting efficient use of shareholder capital.

Steady Revenue Expansion

Revenue has grown at a 56.2% CAGR over the past five years.

Reasonable Valuation

Trades at a P/E of 13.7, below the sector median of 24.8.

Healthy Margins

Maintains a net profit margin of 15.0%.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Dec 2025 Revenue of $911.98M (+13.6% YoY); net profit $145.42M.
  • Trailing 12 Months Year-on-year growth — revenue -7.6%, earnings +171.8%.
  • 5-Year Trend Long-term compounding — revenue CAGR 56.2%.

Growth & Price Performance

Compounded Sales Growth

5 Years:56.25%
1 Year:-7.60%

Compounded Profit Growth

5 Years:-
1 Year:171.77%

Stock Price Performance

1 Year:-28.87%
6 Months:+0.40%
3 Months:+48.16%
1 Month:+3.29%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed
52-Week Range 21% of range
$40.05 $143.99
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMABelow
  • RSI (14)58.58 · Neutral
Price Performance
1M+3.29%
3M+48.16%
6M+0.40%
1Y-28.87%
Valuation vs Sector

P/E of 13.72 is below the sector median of 24.83 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 56.2% over 5 years.
  • Generates positive free cash flow.

CONS

  • Trading 56.8% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
13.72
Industry PE
24.83
Forward P/E
40.43
PEG Ratio
-
Book Value
$28.56
Price to Book
2.69
P/S
2.47
EV/EBITDA
25.39
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
56.25%
Profit 5Y
-
Revenue (YoY)
-7.60%
Earnings (YoY)
171.77%

Profitability & Returns

ROCE
6.28%
ROE
17.97%
ROA
3.91%
Profit Margin
15.03%
Op Margin
-0.26%
Gross Margin
86.13%
EPS (Latest Qtr)
$0.01
EPS (TTM)
$4.53

Balance Sheet & Liquidity

Debt/Equity
3.52
Quick Ratio
5.96
Current Ratio
8.55
Debt
$29.09M
Total Assets
$925.99M
Current Assets
-
Working Capital
-

Ownership

Promoter Holding
1.18%
Chg in Prom Hold
0.02%
FII / Inst Holding
130.27%
Chg in FII Hold
-0.13%

Financial Snapshot

Enterprise Value
$1.80B
Total Revenue (TTM)
$898.74M
EBITDA
$71.33M
Free Cash Flow
$94.64M
Operating Cash Flow
$157.07M
Shares Outstanding
28.91M
Gross Margin
86.13%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 INSP Inspire Medical Systems, Inc. R3KPHARMA 62.14 13.72 $1.80B 0.00% 6.28% 17.97% 56.25% -
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,123.91 37.80 $1.00T 0.60% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 269.12 31.22 $648.55B 1.98% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 248.78 70.48 $439.62B 2.78% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 148.46 118.77 $366.28B 2.31% - 6.96% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 400.84 25.74 $359.79B 2.47% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 137.70 20.80 $261.73B 3.36% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 160.04 23.99 $248.20B 2.00% 15.97% 21.96% 9.82% 45.96%
9 TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA 603.02 32.49 $222.97B 0.29% 8.14% 13.51% 8.81% 12.95%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Mar 2026Jun 2026
Revenue ----10.04M10.94M13.05M-16.25M18.03M20.86M26.91M21.35M12.18M35.84M46.01M40.35M52.96M61.69M69.38M91.39M109.19M127.90M151.09M153.30M164.01M195.88M203.19M201.32M217.09M224.50M204.58M200.58M
Gross Profit 4.10M4.67M5.71M8.08M7.75M8.84M10.59M13.37M13.40M14.94M17.41M22.67M18.05M10.23M30.63M38.85M34.37M45.44M53.06M59.38M77.21M89.40M108.01M126.84M128.92M139.25M166.04M170.79M170.61M182.41M192.73M176.91M171.46M
Operating Income -4.12M-4.38M-3.65M--5.20M-5.64M-4.65M--8.78M-8.18M-8.65M--16.44M-22.81M-9.89M--15.69M-12.54M-9.80M-16.06M-14.01M-17.19M-19.50M-16.60M-13.47M-15.22M5.10M14.32M-1.49M-3.32M9.64M-1.12M-514.00K
Net Income -4.48M-4.76M-4.02M-4.25M-6.50M-5.86M-4.69M-4.78M-8.27M-7.65M-8.25M-9.08M-16.25M-23.09M-10.38M-7.48M-16.22M-13.09M-10.35M-16.69M-14.49M-16.85M-15.42M-11.95M-8.54M-10.01M9.79M18.50M2.99M-3.59M9.93M-11.29M314.00K
Diluted EPS --------------0.88-0.39--0.60-0.48-0.38-0.61-0.53-0.60-0.53-0.41-0.29-0.340.320.600.10-0.120.34-0.390.01
R&D Expense 1.59M1.74M1.18M-1.73M1.74M1.77M-2.60M2.85M3.62M-5.44M6.06M7.31M-8.15M9.29M9.61M11.87M14.53M20.99M25.52M30.82M29.14M28.85M28.86M26.08M27.80M26.21M24.21M25.83M24.70M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 16.43M28.57M50.59M82.05M115.38M233.39M407.86M624.80M802.80M911.98M
Gross Profit 12.52M22.55M40.54M68.41M97.76M200.12M341.74M528.22M679.82M778.76M
Operating Income -17.25M-16.00M-20.38M-34.90M-56.21M-39.85M-47.59M-40.27M36.08M50.95M
Net Income -18.53M-17.51M-21.83M-33.24M-57.20M-42.04M-44.88M-21.15M53.51M145.42M
Diluted EPS ----1.40-2.19-1.54-1.60-0.721.754.89
R&D Expense 7.09M6.19M7.39M12.84M26.09M37.35M68.64M116.54M114.13M103.17M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2015Dec 2016Dec 2017Dec 2018Jan 2019Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --25.09M200.08M200.09M181.25M281.19M295.08M564.88M676.81M808.38M907.32M
Total Equity -1.14M-6.61M1.33M164.00M-139.84M229.75M229.05M496.01M572.51M689.70M781.16M
Cash & Equivalents 12.13M6.68M8.96M97.29M-22.86M190.52M214.47M441.59M185.54M150.15M104.81M
Long Term Debt ---24.50M-24.50M24.50M24.50M----
Total Liabilities --23.76M36.08M36.09M41.42M51.44M66.04M68.87M104.30M118.69M126.16M
Current Liabilities --7.15M11.15M11.17M16.86M20.73M41.31M61.19M78.11M88.50M96.06M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -17.95M-15.79M-18.69M-32.85M-53.05M-20.12M11.57M24.65M130.25M116.98M
Investing Cash Flow -306.00K-7.60M-83.39M-43.56M86.63M29.14M-19.60M-294.82M-113.12M21.45M
Financing Cash Flow 12.81M25.66M190.38M1.96M134.06M14.95M235.08M13.95M-52.39M-183.45M
Capital Expenditure -306.00K-412.00K-250.00K-2.74M-2.46M-4.67M-9.10M-23.63M-39.12M-38.50M
Free Cash Flow -18.25M-16.20M-18.94M-35.59M-55.50M-24.79M2.47M1.02M91.12M78.48M
Share Buybacks ------000175.02M

Ratios (Annual)

Figures in %.

Metric Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % 76.2%78.9%80.1%83.4%84.7%85.7%83.8%84.5%84.7%85.4%
Operating Margin % -105.0%-56.0%-40.3%-42.5%-48.7%-17.1%-11.7%-6.4%4.5%5.6%
Net Margin % -112.8%-61.3%-43.1%-40.5%-49.6%-18.0%-11.0%-3.4%6.7%15.9%
ROE % 280.4%-1,319.6%-13.3%-23.8%-24.9%-18.4%-9.0%-3.7%7.8%18.6%
ROCE % --89.2%-10.8%-21.2%-21.6%-15.7%-9.4%-6.7%5.0%6.3%

Shareholding Pattern

Insiders
1.18%
Institutions
130.27%
Public Float
131.82%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 16.39% 4.74M $363.75M
2 Wellington Management Group, LLP 8.24% 2.38M $182.94M
3 Vanguard Portfolio Management LLC 7.23% 2.09M $160.39M
4 Soleus Capital Management, L.P. 6.68% 1.93M $148.30M
5 AQR Capital Management, LLC 6.42% 1.86M $142.57M
6 UBS Group AG 5.69% 1.65M $126.34M
7 Shaw D.E. & Co., Inc. 5.09% 1.47M $112.90M
8 Nomura Holdings Inc. 4.74% 1.37M $105.14M
9 Deerfield Management Company, L.P 4.49% 1.30M $99.57M
10 Vanguard Capital Management LLC 4.40% 1.27M $97.58M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for INSP

Google News Fri, 04 Sep 2026

Inspire Medical Systems (INSP): Buy, Sell, or Hold Post Q2 Earnings? - finance.yahoo.com

<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxQTXQtd3luam50QTlOTlBLVlFZX0VGZ3Rpa3hqQ3o3MmtQeDJZd0liR2tHMmVta3c4amV5ZHJ2YWt3RERaaDNiaG1EbThuZlg1eTEwdWN5NFUwZVdFZlpyR0V6MUdQSnptTXBZcVEwTFA1bi15b0dQM0RPYU9TNmw5aThLZ1BKYjc4TGpCRU…

Google News ue, 04 Aug 2026

Why Are Inspire Medical Systems (INSP) Shares Soaring Today - StockStory

<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxNc2pXVjZmc05WRk1EZzBJdjZrd0RPNnpJQTF0LVNiWlZQUnpfdVRCSTB2QW9jRzE0cjhKX1RvVXVuSW5QcXJsMG4zNlp0dkg4dmVqVDl2YThUTUdLdjFORTZiU3pBRDEwcUpMeEY5QW90M3RiREpKaWFpal9Lbm9RbmE3VHNoT3BwQVMzSm…

Google News Fri, 04 Sep 2026

Is Inspire Medical Systems (INSP) Undervalued After Its Earnings Beat And Higher 2026 Guidance? - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi2gFBVV95cUxOSTdhYzZKaHBYR1hnWG5vWGxmaTlMaURkVkp3LUc0Z1dya1Etanc4WWQ1MkxUN1NMdlkxYmNUX3ozdURpZmVJeFhRSWVuYnVYQzl6clZoRU5lVWFXM2JYNHo3WnlwWjhlZFB6ZmQ1V0hqaVVNZkxjYzJhU3lZWlZ4amR3R09PNm1mYWk2ND…

Google News hu, 20 Aug 2026

Here's Why You Should Add INSP Stock to Your Portfolio Now - tradingview.com

<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxPR1hDQUw3a05TRlRnclZfTFJNNnFYZC1RM2t0MDNqUzViYnd4ZHlNTTRoUlU4WnoyT3dfSEhXTWZST1pkZzNLZ1Bod1IxXzB6UV9qVEVqeFZLaTNqbXdDODRRTHR1aDFZd3FfbzFaS3NtazdLb1BWeGx3SGF2Z3BjVHYyYTFlYVB6czVCWk…

Google News hu, 03 Sep 2026

Inspire Medical (INSP) awards 6,350 RSUs vesting over 3 years - Stock Titan

<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxPdzVYSGRmVjFacUhGelU1eTZ2NUNPbDMyZElENFdPc2d5a1Z3TXcyTHV3QlhiS1ZtVEkyZ29PeXFGd2xqLTdQNzVSV2l3RVpKYV9NN2pEMGZFSkhTOElmSmI0T1FvZHBPYnNmVGdtR19rV0ZNWnVlZnFNMWYwamtPTndqTzR3Z09NcXRiWk…

Google News Wed, 02 Sep 2026

Why Is Inspire (INSP) Down 4.1% Since Last Earnings Report? - Eastern Progress

<a href="https://news.google.com/rss/articles/CBMi0wFBVV95cUxOcy1qSjlvVTZQRVNOckNpcXNGOERSSUdHaW9ZdTlDOHhwdkpLbWZpc3ZBUlBwNkhpWlhGaHJkUVdvR2lZdkNoQmVaeW96WmFycnVzSlNJTjM4RmFzQTRlSW1LeWZ6SUg3SmRYMTIxR3Zkd2tDMmtqUHJMX1hMVkt6UC1mMnF6SkNid2xORk…

INSP — Frequently Asked Questions

What is the current share price of Inspire Medical Systems, Inc. (INSP)?

As of 2026-09-19 21:16 PDT, Inspire Medical Systems, Inc. (INSP) trades at $62.14 on NYSE. Its 52-week range is $40.05 to $143.99.

What is the market capitalisation of INSP?

Inspire Medical Systems, Inc. (INSP) has a market capitalisation of $1.80B on NYSE.

What is the P/E ratio of INSP?

INSP trades at a trailing price-to-earnings (P/E) ratio of 13.72. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 2.69.

What is the return on equity (ROE) of INSP?

INSP has a return on equity (ROE) of 17.97%. Its return on capital employed (ROCE) is 6.28%.

Is INSP a good stock to buy?

This page provides a data-driven analysis of Inspire Medical Systems, Inc. (INSP), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space